Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Table 1 Patient characteristics at the time of diagnosis of decompensated HCV-related cirrhosis (n = 1412 patients)

Factor	Value
Clinicodemographic
Sex (male/female)	776/636
Age, years^a	68 (31–97)
Child–Pugh classification (B/C)	1313/99
History of HCC (no/yes)	569/843
BCLC stage^b, n (A/B/C/D)	235/85/16/12
Ascites (no/yes)	823/589
Hepatic encephalopathy (no/yes)	1346/66
Esophageal varices (no/yes)	447/965
Type 2 diabetes mellitus (no/yes)	1051/361
Hypertension (no/yes)	1022/390
Laboratory parameters^a
Serum albumin, g/dL [N = 1412]	3.0 (1.4–4.2)
Serum aspartate aminotransferase, U/L [N = 1412]	64 (5–5942)
Serum alanine aminotransferase, U/L [N = 1412]	42 (1–1306)
γ-glutamyl transpeptidase, U/L [N = 1407]	50 (2–8184)
Serum total bilirubin, mg/dL [N = 1412]	1.4 (0.2–31.1)
Serum creatinine, mg/dL [N = 1412]	0.8 (0.3–17.0)
eGFR, mL/min [N = 1412]	77.8 (2.4–220.5)
Sodium, mEq/L [N = 1388]	140 (113–153)
Ammonia, μg/dL [N = 678]	58 (4–415)
Platelet count, × 10³/mm³ [N = 1412]	8.2 (0.7–61.0)
Prothrombin time, % [N = 1412]	69.1 (7.6–117.4)
α-fetoprotein, μg/L [N = 1373]	34.0 (0.8–13,597,000)
MELD score^c, n [N = 969]	7 (-5–35)

eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HCV, hepatitis C virus
^aMedian (range). All other data are presented as the number of patients
^bThe BCLC stage (A/B/C/D) could be examined in 348 patients
^cThe MELD score could be examined in 969 patients

ISSN: 1471-230X